Prostate cancer (PCa)-specific survival has improved over time for men diagnosed with metastatic PCa. Relative survival has increased over time for men diagnosed with metastatic PCa. Only one in four received second-line therapies after failing first-line therapy. Lead-time bias and new effective therapies have led to apparent improved survival.